Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 1.00 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 1.00 |
| ▸ | CTSD | P07339 | 2/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29470573 | 1.00 | BACE1 (1.00) | BACE1BACE2CTSDAPP | |
| SCHEMBL20899826 | 1.00 | BACE1 (1.00) | BACE1BACE2CTSDAPP | |
| SCHEMBL21527047 | 1.00 | BACE1 (1.00) | BACE1BACE2CTSDAPP | |
| SCHEMBL3510626 | 0.91 | BACE1 (0.91) | BACE1BACE2CTSDAPP | |
| SCHEMBL4218322 | 0.91 | BACE1 (0.91) | BACE1BACE2CTSDAPP | |
| SCHEMBL4211734 | 0.91 | BACE1 (0.91) | BACE1BACE2CTSDAPP | |
| SCHEMBL5029248 | 0.90 | BACE1 (0.81) | BACE1BACE2CTSDAPP | |
| SCHEMBL4211890 | 0.90 | BACE1 (0.81) | BACE1BACE2CTSDAPP | |
| SCHEMBL4216477 | 0.87 | BACE1 (0.84) | BACE1BACE2CTSDAPP | |
| SCHEMBL4208397 | 0.87 | BACE1 (0.82) | BACE1BACE2CTSDAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240241124-A1 | SENSOR | Esya Limited (GB) | 2024-07-18 | — | — | US | disclosed |
| US-11559528-B2 | BACE1 inhibition for the treatment of cancer | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210069205-A1 | BACE1 INHIBITION FOR THE TREATMENT OF CANCER | THE CLEVELAND CLINIC FOUNDATION | 2021-03-11 | — | — | US | disclosed |
| US-20150335614-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR | PHOLORONOL INC (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150335614-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR | PHOLORONOL INC (US) | 2015-11-26 | — | — | US | disclosed |
| US-20130196976-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR | Phloronol, Inc. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196976-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR | Phloronol, Inc. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120122822-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR | Phloronol, Inc. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122822-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR | Phloronol, Inc. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010047372-A1 | 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559528-B2 | BACE1 inhibition for the treatment of cancer | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 91/4885 |
| US-20210069205-A1 | BACE1 INHIBITION FOR THE TREATMENT OF CANCER | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 91/4885 |
| US-20130196976-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 87/4885 |
| US-20120122822-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 87/4885 |
| US-20150335614-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 87/4885 |
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885CTSD 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.